|Home | About | Journals | Submit | Contact Us | Français|
The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations and aberrations in gene expression. As few of these changes are shared between individuals or types of cancer, the best source for eliciting broad-spectrum tumor immunity remains each patient’s own tumor. Previously, we have demonstrated that combining blockade of the T-cell negative costimulatory molecule CTLA-4 and vaccination with irradiated B16 tumor expressing GM-CSF (Gvax) promotes rejection of established murine melanomas. Here we show that, like GM-CSF, the cytokine Flt3-ligand (Flt3L) expressed in B16 and coupled with CTLA-4 blockade promotes both prophylactic and therapeutic rejection of B16. When administered at the site of growing tumor Gvax fails to prevent tumor outgrowth in any mice, whereas the B16-Flt3L vaccine (Fl3vax) induces the rejection of 75% of melanomas implanted 3 days prior to vaccination. Relative to Gvax, Fl3vax promotes greater infiltration of both the vaccine site and the tumor site by CD8+ T-cells and “sentinel” and plasmacytoid dendritic cells. Gvax and Fl3vax did not synergize when used in combination in treating B16 melanoma even in the context of CD25+ Treg depletion. Further, we show that a combination of Flt3L expression and CTLA-4 blockade can also promote the rejection of established TRAMP prostate adenocarcinomas, proving the utility of this treatment extends beyond melanoma. Engineering Flt3-ligand to be constitutively secreted and attaching an IgG2a tail yielded a B16 vaccine which, when combined with CTLA-4 blockade, prevented the outgrowth of significantly more 5-day implanted B16-BL6 tumors than did Gvax.
Irradiated tumor cells can be reintroduced as a vaccine, however the induced anti-tumor responses are ineffective due to lack of immune co-stimulation(1). GM-CSF has proven the most capable adjuvant for transforming irradiated tumor vaccines into mediators of tumor protection and sometimes rejection(2). Cellular tumor vaccines rely on cross-presentation of tumor antigens by professional antigen presenting cells (APCs)(3). GM-CSF enhances this process both by inducing differentiation and maturation of APCs such as dendritic cells (DCs), and by chemoattracting granulocytes, macrophages, and lymphocytes to the vaccine site(4).
We sought to determine whether other molecules which may enhance cross-presentation could substitute for GM-CSF in converting irradiated tumor into an effective vaccine. The cytokine Fms-like tyrosine kinase 3-ligand (Flt3L) supports the survival, proliferation, and differentiation of hematopoeitic progenitors(5), and both induces and chemoattracts dendritic cells(6, 7). Recombinant Flt3L promotes tumor regression in some tumor models(8), but alone cannot reject pre-implanted poorly immunogenic tumors like B16 melanoma. The chemokine IP-10/CXCL10 is known both to chemoattract monocytes, NK cells, and TH1 lymphocytes (9), and to have anti-angiogenic properties(10). IP-10 can function in immunotherapy and has been associated with graft rejection and GvHD in transplantation(11–13). The chemokine MCP-3/CCL7 potently attracts lymphoid and myeloid cells(14–17). MCP-3 can also promote anti-tumor responses and has been implicated in graft rejection and GvHD(18–20). The adjuvant activity of GM-CSF for tumor vaccination has been best characterized in the B16 melanoma model, thus we compared these candidate adjuvants in this setting.
Vaccination with irradiated B16 expressing GM-CSF can protect mice against subsequent tumor challenge, and can slow the growth of, but not reject pre-implanted tumors(2). To reject established melanomas, B16-GMCSF (Gvax) vaccination must be combined with antibody blockade of the T-cell negative costimulatory receptor CTL-associated antigen 4 (CTLA-4)(21). Blockade of CTLA-4/B7 binding using antibodies exerts a powerful adjuvant effect on T-cells and can induce the rejection of many transplantable tumors. In the case of less immunogenic tumors such as B16 melanoma or TRAMP prostate adenocarcinomas, CTLA-4 blockade alone may slow the growth of, but cannot reject pre-implanted tumors(22–24). The combination of CTLA-4 blockade and Gvax vaccination, however, synergizes to induce rejection of established tumors in these models(21, 25, 26), and in some clinical trials(27, 28).
Using retroviral vectors, we created B16 cell lines expressing GM-CSF (Gvax), Flt3L (FL3vax), IP10, or MCP-3. We measured the efficacy of these vaccines in prophylaxis and treatment in combination with CTLA-4 blockade. We next compared the relative efficacy of each vaccine when administered at the tumor site versus on the opposite flank. These experiments revealed distinct treatment profiles for GM-CSF, Flt3L, and IP-10 expressing vaccines and strongly validated Flt3L as a cellular tumor adjuvant. We found that Fl3vax and Gvax did not synergize when used for combination treatment of B16 melanomas or TRAMP adenocarcinomas. We thoroughly characterized the lymphocytic infiltrates of both the vaccine sites and tumors of mice receiving Gvax, Fl3vax, or the combination in the context of CTLA-4 blockade. Also, we sought to determine the utility of Flt3L as a cellular tumor adjuvant outside of the B16 system by comparing it to GM-CSF for the treatment of established TRAMP tumors. Finally, we re-engineered our FL3vax to optimize the bioactivity of Flt3L and compared the enhanced vaccine to Gvax in treating 5-day established B16 melanomas.
C57BL/6 mice (4–6 week males, Jackson) were cared for accordance with NIH and AALAC regulations. Experiments were all approved by the MSKCC IACUC.
Mouse α-CTLA-4 (9D9), hamster α-CTLA-4 (9H10), α-CD25 (PC61), α-CD4 (GK1.5), α-CD8 (2.43), and α-NK1.1 (PK136) were purified at the MSKCC antibody facility. Antibodies and gating for 9-color flow cytometry are outlined in Supplemental Table 2.
B16/BL6 cells were used for tumor challenge and for the creation of all vaccine lines and were maintained as described(21). TRAMP-C2 cells were used in all prostate cancer experiments and for creation of TRAMP-GMCSF and TRAMP-Flt3L and grown as described(29).
Murine GM-CSF, Flt3L, IP10 and MCP3 cDNAs were cloned into the pMG-Lyt2 retroviral vector. This vector resembles pGC-IRES except that a truncated form of murine CD8α is used for selection (30). Recombinant virus production and infection were performed as described except that VSV-G and 10A1 envelope proteins were used(31).
Mice were injected in the flank i.d. at day 0 with the indicated number of B16-BL6 cells and treated on days 3, 6, and 9 (5, 8, 11 for Figures 3,,6)6) with 1 × 106 irradiated (150 Gy) gene-modified B16 cells on the contralateral flank and 100ug α-CTLA-4 (9D9) intra-peritoneally. All vaccinations were on the opposite flank from tumor except in Figure 3 where “local” groups received their vaccinations on the same flank as tumor challenge. For FL3vax/Gvax combination vaccines all were normalized to a total dose of 2×106 B16 cells/vaccine by addition of B16-Lyt2 cells. Where indicated, Treg depletion was achieved by a single 400ug injection of α-CD25on Day -4.
Mice were injected in the flank i.d. at day 0 with 1×106 TRAMP-C2 prostatic adenocarcinoma cells and treated on days 2, 5, and 8 with 1 × 106 irradiated (120 Gy) gene-modified TRAMP-C2 cells on the contralateral flank and 100ug α-CTLA-4 (9H10) i.p.
Mice received two gene-modified B16 vaccines i.d. 4 days apart in 30% collagen matrix (Matrigel–BD) coupled with 100ug of α-CTLA-4 i.p. Gvax, Fl3vax, and Gvax/Fl3vax vaccines were formulated as described above. One day after the second vaccination, mice were euthanized, the vaccine site was excised, and infiltrating lymphocytes were obtained after disruption and Ficoll purification. Infiltrating cells were stained with fluorophore-conjugated monoclonal antibodies and analyzed by 9-color flow cytometry on a Cyan (Dako) (Supplemental Table 2).
Mice were injected in the flank i.d. at day 0 with 10,000 B16/BL6 cells in 30% collagen matrix (Matrigel – BD). Mice were vaccinated as described for Day-3 tumor treatment. 13–15 days after tumor challenge, mice were sacrificed, and TILs were obtained from tumors and purified and stained as described for intra-vaccine lymphocytes above
We compared the adjuvant efficacy of two chemokines, MCP-3 and IP-10, and the cytokine Flt3-Ligand (Flt3L) to the established adjuvant cytokine GM-CSF (Supplemental Table 1). Retroviral vectors were constructed with a marker gene directly linked to the adjuvant gene ensuring that levels of the two genes were proportional (Supplemental Figure 1A). Cell lines were normalized by cell sorting to equivalent high levels of marker gene expression (Supplemental Figure 1B,C) and then expression of the adjuvant gene was confirmed by intracellular cytokine staining (Supplemental Figure 1D). This system allowed rapid generation of vaccine cell lines expressing levels of all adjuvant genes within or exceeding the known ED50 ranges by ELISA (Supplemental Table 1).
Mice were vaccinated twice with irradiated tumor cells prior to being challenged with B16-BL6 melanoma cells on the opposite flank. Compared to B16-YFP, B16-GMCSF (Gvax), B16-Flt3L (FL3vax), and B16-IP10 all showed statistically significant activity in preventing tumor growth (Figure 1A). Although MCP3 protected more mice than B16-YFP alone, its effect was not significant.
The YFP marker created high variability in the B16-YFP control(Figure 1A), and was difficult to normalize in expression between lines (Supplemental Figure 1B), so for all subsequent experiments a non-immunogenic truncated Lyt-2 marker was used instead. These Lyt2 vectors yielded similar prophylactic data to the YFP vectors (Supplemental Figure 2) but were easier to normalize (Supplemental Figure 1C) and lacked the potentially confounding immunogenicity of YFP. Compared to B16 alone, B16-Lyt2 grew at the same rate in untreated mice (Data not shown).
To compare our adjuvant genes to GM-CSF, we tested their ability to synergize with CTLA-4 antibody blockade to treat 1×104 B16 melanoma cells implanted 3-days earlier. Individually neither any of the cellular vaccines nor CTLA-4 blockade alone slows tumor growth (Figure 1B) or is curative. When coupled with CTLA-4 blockade, treatment with Gvax or Fl3vax resulted in 63% and 60% tumor-free mice(Figure 1C). By comparison, IP-10 and MCP3 showed much less capacity to prolong survival of B16-bearing mice. Gvax and Fl3vax were also most effective in slowing tumor growth (Figure 1D), while B16-MCP3 had no effect on tumor growth and was not studied further.
As melanoma lesions can sometimes be directly accessed for treatment, we tested the efficacy of Gvax, Fl3vax, and B16-IP10 both locally (at the tumor site) and distally (on the opposite flank) in combination with CTLA-4 blockade.
Surprisingly, Gvax showed vastly diminished efficacy in treating mice which had been challenged with 2×104 B16 cells 3-days prior when administered locally versus distally both in terms of tumor free survival (Figure 2A) and tumor size at first measurement (Figure 2B). No tumor growth curve is provided because granulomas evoked by the vaccine at the tumor site cannot be distinguished from tumor for 3–4 weeks. Unlike Gvax, Fl3vax was significantly more effective when administered at the tumor site versus the opposite flank resulting in 75% tumor-free mice. B16-IP10 which showed little effect distally, proved to be effective when given at the tumor site.
Gvax can induce myeloid suppressor cells under certain conditions suggesting that the failure of Gvax proximal to tumor may be due to the interaction of the myeloid cells evoked by the vaccine and the tumor microenvironment(32, 33). Our Gvax line produces 360ng/1×106 cells/24hrs of GM-CSF which is within the optimal immunogenicity range, and well below the levels which have been described as inherently suppressive(32, 34). These data indicated there were likely to be significant differences in the cellular subsets evoked by each vaccine, therefore sought to determine if Gvax and Fl3vax would cooperate in eradicating B16 melanomas.
In order to test the potential for Fl3vax and Gvax to synergize in rejecting B16 melanomas, we waited until 5 days following tumor challenge to begin treatment. Gvax and FL3vax demonstrated similar efficacy; however, combination treatment with both vaccines prevented tumor outgrowth in equal or fewer mice compared to either alone(Figure 3A). In addition, tumors in mice receiving the dual cytokine vaccine grew at similar or faster rates compared to mice receiving either vaccine alone (Figure 3B).
Both B16-Flt3L and B16-GMCSF vaccination are known to elicit Tregs which dampen anti-tumor responses(35, 36). To determine if these two cytokines would synergize in the absence of Tregs, we repeated the above experiments in mice which had been pre-depleted of CD25+ cells. Once again, the combination of Gvax and Fl3vax was clearly no more effective than either vaccine alone (Figure 3C), although the potency of all vaccines was enhanced by Treg pre-depletion. Tumors in mice vaccinated with both B16-Flt3L and B16-GMCSF, although small, grew at similar or faster rates compared to mice receiving either vaccine alone (Figure 3D). To further understand the mechanisms of action of each these vaccines, we examined the cells infiltrating both the vaccine and tumor sites for each.
Published analysis for Gvax indicated that CD8+ T-cells and NK1.1+ cells were the critical populations for rejecting B16 tumors(26). We found in mice depleted of CD8+ cells or NK1.1+ cells, Fl3vax + α-CTLA-4 vaccination lost virtually all capacity to promote rejection of tumors implanted 3 days earlier (Supplemental Figure 3A), and tumors grew at rates similar to untreated mice (Supplemental Figure 3B). Also, a much higher percentage of CD4 depleted mice developed tumors and those tumors grew faster than in mice pre-depleted of Tregs (which are also depleted by α-CD4). Thus, we found that CD8+ T-cells, CD4+ T-cells, and NK1.1+cells all play important roles in rejecting tumors following Fl3vax vaccination with CTLA-4 blockade. We hoped that a more detailed study of the vaccine and tumor infiltrating lymphocyte populations evoked by each vaccine would further clarify the adjuvant mechanics of each, and perhaps suggest reasons for their lack of synergy.
Mice were given 2 vaccinations with Gvax, FL3vax, or a combination of both with α-CTLA-4 antibody and 24hrs later the lymphocytes infiltrating the vaccine site were isolated and typed (Supplemental Table 2). For both Gvax and Fl3vax, the vaccination site infiltrate was dominated by granulocytes and macrophages (Figure 4A). Despite this similarity, the B16-Flt3L site contained a 2–3 fold higher fraction of B cells, NK cells, and CD11b−/lo DCs relative to the B16-GMCSF site. Most strikingly, plasmacytoid DCs (pDCs) and CD8+ T-cells comprised 5.5-fold and 8.5-fold higher fractions of the Fl3vax site compared to that of Gvax. Tregs, granulocytes, and monocytes/CD11bmed/hi DCs were more abundant in the B16-GMCSF site. The CD11b−/lo DC population favored by Flt3L consists primarily of “sentinel” and pDCs, whereas the CD11c+CD11bmed/hi population elicited by GM-CSF is a mixture of monocytes and “inflammatory” DCs(37). The most striking difference between the Gvax/Fl3vax combination and either vaccine alone was the relative lack of NK cells and T-cells, especially CD8+ T-cells.
We next decided to investigate how the differences observed in the composition of the vaccine sites would impact the profile of the lymphocytes infiltrating the tumor.
To dissect the differential effects of Gvax, Fl3vax, and combination vaccination in treating B16, we undertook a more comprehensive analysis of the tumor infiltrating lymphocyte (TIL) population. Following tumor implantation and 3 vaccinations, TIL were isolated and characterized (Figure 4B). We found that overall TIL frequency (i.e. the extent of infiltration) in mice receiving the Gvax, Fl3vax, and Gvax/Fl3vax vaccines with CTLA-4 blockade was similar and substantially higher than in untreated mice (Supplemental Figure 4). Similar to the vaccine site infiltrate, TIL from Fl3vax treated mice contained higher proportions of “sentinel” DCs, pDCs, NKDCs, and CD8+ T-cells and lower levels of “inflammatory” DCs relative to TIL from mice receiving Gvax. Unlike the vaccine site, FL3vax inoculated mice also had higher levels of Tregs in their tumors. Despite having large numbers of granulocytes, macrophages, and DCs, TIL from the combination vaccinated mice contained the lowest percentage of CD8+ T-cells.
Tregs suppress cytotoxic T-cells and, in the case of B16, elevated ratios of CD8+ T-cells to FoxP3+ Tregs within the tumor correlate with successful treatment(35). Both Gvax and Fl3vax increase the ratio of CD8+ T-cells to Tregs within the tumor, especially in conjunction with α-CTLA-4 antibody (Figure 4C). Of the mice receiving CTLA4 blockade, this ratio is lowest in the combination vaccine group but not to an extent which explains it’s reduced immunogenicity. Although Tregs do make up a larger percentage of the TIL elicited by Fl3vax relative to Gvax, the even higher level of CD8+ T-cells also elicited by Fl3vax yielded the highest CD8/Treg ratios in TIL.
As CD11b+,GR1+ candidate myeloid suppressor cells can be classified as either macrophages or granulocytes in our typing system depending on the other markers they express, we decided to analyze their relative enrichment in the tumors of vaccinated mice as a separate population. We find that vaccination with Gvax, with or without CTLA-4 blockade, results in significantly higher percentages of CD11b+,GR1+ cells in TIL compared to mice receiving FL3vax or to untreated mice (Figure 4D). This enhanced infiltration by myeloid suppressor cells may explain the failure of Gvax to cure tumors when given at the tumor site where much higher concentrations of GMCSF would be present around the tumor.
Having demonstrated the efficacy of Fl3vax for treating pre-implanted B16 melanomas in conjunction with CTLA-4 blockade, we sought to determine whether it would also have utility for the treatment of other poorly immunogenic tumors.
We used retroviral vectors to create GMCSF and Flt3L expressing vaccines derived from the TRAMP-C2 prostate adenocarcinoma. The majority of TRAMP-C2 tumors can neither be cured by Gvax or CTLA-4 blockade alone, but are susceptible to combination therapy. We found that both TRAMP-GMCSF and TRAMP-Flt3L could protect 100% of mice from outgrowth of 1-day pre-implanted low dose (5×105 cells) TRAMP-C2 tumors when combined with CTLA-4 blockade (Data not shown). For this reason we sought to block the outgrowth of a higher TRAMP-C2 challenge (1×106 cells) with vaccination on days 2, 5, and 8.
Treatment with TRAMP-GMCSF, TRAMP-Flt3L, and a combination of both resulted in similar percentages of tumor-free mice when combined with CTLA-4 blockade (Figure 5A). The overall tumor growth rate was also not significantly different between mice receiving either vaccine (Figure 5B). As with B16, combination therapy with TRAMP-GMCSF and TRAMP-Flt3L failed to show any efficacy beyond that of either treatment alone. These data demonstrate that the adjuvant utility of Flt3-ligand extends beyond the B16 melanoma system.
Whereas GMCSF has been shown to plateau in adjuvant efficacy at a relatively modest level(34), we wondered if the efficacy of Flt3L might increase with higher levels of expression. A preliminary study suggested that Gvax decreased in efficacy with increasing dose, while FL3vax maintained or slightly increased its effect at higher doses (Supplemental Figure 5). This system suffered from many limitations, however, including veterinary complications due to the large vaccine dose (5×106/injection), as well as the potential to saturate the amount of serum protease available to release Flt3-ligand from the cell membrane in its bioactive form. We decided instead to create two new vaccines which constitutively secrete Flt3L. One of these is truncated at the site where membrane cleavage occurs in the wild type form (secFL3vax), and the other is truncated at the same site and joined to a mouse IgG2a constant region for increased stability and to enable dimerization (sFL3vaxIg). Each of these lines was normalized to the same Lyt2 expression level as FL3vax and found to produce between 900 and 1000 ng/1×106cells/24hr of Flt3L in vitro.
To compare these new vaccines to the original FL3vax and Gvax, we tested their ability to synergize with CTLA-4 blockade to block outgrowth of B16 melanoma cells injected 5-days prior to treatment. In this setting, sFL3vaxIg cured a significantly higher percentage of mice than did Gvax or any of the other Flt3L-based vaccines (Figure 6A). The tumors of mice receiving the sFL3vaxIg vaccine with CTLA-4 blockade also grew at a significantly slower rate than those of any other treatment group in each of 3 individual experiments (Figure 6B). These experiments demonstrated that this enhanced Flt3L-expressing B16 vaccine was superior to Gvax for use in treating B16 melanoma in conjuction with CTLA-4 blockade.
We pursued a rational approach to determine if molecules designed to enhance infiltration of a vaccine site by APCs could substitute for GM-CSF in rendering autologous tumor immunogenic. In our hands, Flt3L and IP10 function effectively as adjuvants for B16 melanoma vaccination as they protected mice from subsequent tumor challenge when used prophylactically (Figure 1A), and were capable of effectively treating pre-implanted B16 tumors when combined with CTLA-4 blockade (Figure 1C). Most impressively, Fl3vax, like Gvax, proved capable of synergizing with α-CTLA-4 treatment to completely prevent the outgrowth of a majority of 3-day established B16 melanomas (Figure 1C,D).
As we investigated the application and mechanics of FL3vax further, we found that in some settings its efficacy exceeded that of Gvax. One of the most striking findings we report is the inability of Gvax + α-CTLA-4 therapy to prevent tumor growth in any mice bearing 3-day pre-implanted B16 melanomas when given at the tumor site versus on the opposite flank (Figure 2). In contrast, Fl3vax showed similar efficacy to Gvax when given on the opposite flank, but resulted in 75% of mice being tumor free when given locally. As further evidence for Gvax’s lack of local immunogenicity, we and others have found little or no reduced growth of B16-GMCSF cells in vivo relative to untransduced B16 cells (38). Most interestingly, the Fl3vax elicited infiltrate seems resistant to cooptation by the tumor microenvironment and likely benefits from reduced trafficking requirements and sustained antigen availability. Relevantly, we later found that even distal Gvax inoculation increases the percentage of CD11b+GR1+ candidate myeloid suppressor cells in B16 tumors relative to FL3vax treated or untreated mice (Figure 4D). For malignancies such as melanoma in which tumor sites are accessible to direct injection, these data provide a compelling rationale for clinical evaluation of Fl3vax in conjunction with CTLA-4 blockade.
The differences in local vs. distal efficacy between Fl3vax and Gvax suggested there were distinct mechanisms underlying their immunogenicity and we hoped they might synergize when used in combination. In both the B16 and TRAMP tumor models, however, Gvax and FL3vax failed to cooperate when used in combination even in the context of Treg depletion (Figure 3,,5).5). To better understand this observation as well as the underlying differences between Fl3vax and Gvax, we isolated and characterized the lymphocytes infiltrating both the vaccine site and tumor in response to each vaccine.
Compared to vaccines expressing GM-CSF, we find a higher percentage of CD11b−/loDCs and much higher proportion of pDCs and CD8+ T cells infiltrating the Flt3L site (Figure 4A). CD4+FoxP3+ Treg cells are known to suppress the activity both of CD8+ T-cells and DCs(39, 40) and we have reported that higher CD8/Treg ratios within tumors are indicative of effective vaccination(35). Within the Fl3vax vaccination site there are few Treg cells suggesting a favorable environment for immune priming. Compared to either vaccine alone, the combination vaccine site contains very low levels of T and NK cells suggesting a possible qualitative defect in the FL3vax+Gvax generated APCs.
The FL3vax + α-CTLA-4 evoked TIL contains the highest levels of CD8+ T-cells, pDCs, and CD11b−/loDCs we observed (Figure 4B,C) and the lowest levels of CD11b+GR1+ cells (Figure 4D). The tumors of FL3vax recipient mice are substantially infilitrated by Tregs; however, the increase in CD8+ T-cells exceeds that of Tregs and preserves a highly advantageous CD8+ T-cell/Treg ratio. The synergy we observe between Treg depletion and Fl3vax combination therapy may be due to the removal of suppression from these large numbers of CD8+ T-cells and DCs (Supplemental Figure 3).
A prior publication reported that B16-GMCSF was more effective preventively compared to B16-Flt3L, and that GM-CSF elicited a qualitatively and quantitatively, based on higher B7–1 expression, superior dendritic cell infiltration of the vaccine(38). We found the levels of Flt3L produced by their vaccine are substantially lower than ours by both ELISA (290 vs 950 ng/1×106cells/24hr) and flow cytometry (Supplemental Figure 6) which we believe may explain the disparity between our results. Also the differences in our B16 systems (BL6 vs. F10), or in the timing of our prophylactic vaccinations could be relevant. Besides our own observations, a wealth of data now exists which not only suggests that Flt3L potently generates highly stimulatory DCs(7, 8, 41), but also that those DCs, despite lower expression of B7–1, may be superior for T-cell priming compared to those generated by GM-CSF(42, 43).
We observed that Flt3L’s efficacy seemed to increase with higher doses (Supplemental Figure 5), whereas it is known that GMCSF’s adjuvant activity decreases at higher expression levels(32). In order to increase the bioactivity of our Flt3L transgene, we fused the extracellular domain to a mouse Ig constant region creating an enhanced vaccine termed sFL3vaxIg. Compared to Gvax, sFL3vaxIg was able to prevent outgrowth of more 5-day pre-implanted B16-BL6 tumors in conjuction with CTLA-4 blockade (Figure 6). Taken together these observations suggest that Fl3vax may be a broadly useful vaccine for the treatment of human malignancies especially in conjunction with CTLA-4 blockade.
James P. Allison is an investigator of the Howard Hughes Medical Institute and holds the David H. Koch Chair in Immunologic Studies at the Memorial Sloan-Kettering Cancer Center.
Dr. Allison is a paid consultant for Cell Genesys, Bristol-Myers Squib, and Medarex and is the primary inventor on the Patent “Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling”.